Catalog No.
Product Name
Application
Product Information
Citations
-
Antibacterial Agent
MmpL3-IN-2 is an inhibitor of the MmpL3 protein, a key component in the cell wall biosynthesis of Mycobacterium tuberculosis. This compound demonstrates low cytotoxicity and moderate metabolic stability, making it suitable for antibacterial research, particularly in the study of tuberculosis. Its selective activity against MmpL3 positions it as a promising candidate for the development of new therapeutic strategies targeting mycobacterial infections. -
Antibacterial/Anti-inflammatory Agent
Farobin A is a natural compound that exhibits antibacterial and anti-inflammatory activities. It demonstrates efficacy against Streptococcus mutans ATCC 25175 and Streptococcus sobrinus ATCC 33478, making it a valuable agent for antibacterial research. Additionally, Farobin A has been shown to modulate inflammatory responses by reducing the levels of cytokines IL-6 and TNF-α, positioning it as a potential therapeutic target in inflammation-related studies. -
Antibacterial Agent
Antibacterial Agent 56 is a potent antibacterial compound with demonstrated efficacy against a broad range of bacterial strains. Its primary mechanism involves inhibiting bacterial growth through disruption of cellular processes. This reagent is suitable for various research applications, including the study of bacterial resistance mechanisms and the development of novel antimicrobial therapies. -
Bacterial Inhibitor
Ceratotoxin B is an antibacterial peptide derived from the sexually mature females of Ceratitis capitata. It exhibits lytic and antibacterial activity, making it a valuable research tool for studying bacterial inhibition and antimicrobial mechanisms. This peptide can be utilized in studies aimed at understanding bacterial resistance and the development of novel antibacterial agents. -
Bacterial Inhibitor
TP0586352 is a potent LpxC inhibitor specifically designed to target bacterial pathogens, including carbapenem-resistant Klebsiella pneumoniae. This compound exhibits significant antibacterial activity while maintaining a favorable safety profile, as it does not pose cardiovascular risks. Additionally, TP0586352 features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions for further chemical modifications. -
Antimycobacterial Agent
Antimycobacterial agent-2 is a potent antimycobacterial compound that targets Mycobacterium tuberculosis (M.tb) H37Rv. It demonstrates significant anti-mycobacterial activity, with a minimum inhibitory concentration (MIC99) of 0.8 µM. Additionally, this compound exhibits cytotoxic effects on CHO cells, presenting an IC50 value of 48.1 µM. Antimycobacterial agent-2 is suitable for research applications focused on tuberculosis and related mycobacterial infections. -
Antibacterial Agent
Cyclo(prolyltyrosyl) is a cyclic dipeptide known for its antibacterial activity. It exhibits potent effects against various bacterial strains, making it a valuable tool for research into antimicrobial agents. Additionally, this compound demonstrates phytotoxic and cytotoxic properties, providing potential applications in studies related to plant defense mechanisms and cancer research. -
Antibacterial Agent
3-Hydroxyglabrol is an antibacterial agent derived from Glycyrrhiza glabra L. var. typica. It demonstrates significant inhibitory activity against Staphylococcus aureus (ATCC 13709) and Mycobacterium smegmatis (ATCC 607), with a minimum inhibitory concentration (MIC) of 6.25 mcg/mL. This compound is valuable for research focused on infections caused by these bacterial strains, contributing to the development of potential therapeutic strategies. -
Bacterial Inhibitor
Propioxatin B is a tricyclic sesquiterpenoid compound that acts as a bacterial inhibitor. This compound demonstrates significant anti-tuberculosis activity, exhibiting effectiveness against various drug-resistant Mycobacterium tuberculosis strains. In silico docking studies indicate that Propioxatin B binds with bacterial DNA gyrase, suggesting a targeted mechanism of action and potential safety in in vivo applications. -
Antibacterial Agent
Dunnianol is a natural sesqui-neolignan that acts as an antibacterial agent. It demonstrates moderate antibacterial activity against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). This compound is valuable for research applications focused on antimicrobial resistance and the development of new antibacterial therapies. -
Antibacterial
Methyl isocostate is a natural compound with demonstrated antibacterial activity, isolated from the plant Globba schomburgkii. This compound is of interest for its potential applications in antimicrobial research and the development of new antibacterial agents. Its unique properties make it a valuable reagent in studies aimed at understanding bacterial resistance and screening for effective antibacterial pharmaceuticals. -
Bacterial Inhibitor
Drimentine A is a terpenylated diketopiperazine that acts as a bacterial inhibitor, originally isolated from Actinomycete bacteria. It exhibits significant antibacterial activity, making it a valuable tool in microbiological studies. This compound is primarily utilized in research involving bacterial pathogenesis and the development of antimicrobial agents. Unlike its analogs Drimentine B and C, Drimentine A does not possess anticancer activity. -
Antibacterial Agent
Dodicin is an antibacterial agent that exhibits broad-spectrum antimicrobial activity. It targets bacterial cell membranes, disrupting their integrity and leading to cell death. This reagent is suitable for use in various research applications, including microbiological studies and disinfectant efficacy evaluations. -
β-lactamase Inhibitor
β-Lactamase-IN-8 is a potent β-lactamase inhibitor with a broad-spectrum profile, utilizing a cyclic boronate structure to enhance oral bioavailability. It effectively inhibits various β-lactamases, making it a valuable tool for studying antibacterial resistance mechanisms and developing new therapeutic strategies against resistant bacterial strains. Researchers can utilize β-Lactamase-IN-8 for investigating the efficacy of β-lactam antibiotics in microbial infections. -
Antibacterial Agent
DC-159a is an 8-methoxyfluoroquinolone that functions as a broad-spectrum antibacterial agent. This compound demonstrates significant antimicrobial activity against various Gram-positive pathogens, including Peptostreptococcus, Clostridium difficile, and Bacteroides fragilis, with minimum inhibitory concentration (MIC90) values of 0.5, 4, and 2 μg/mL, respectively. DC-159a is suitable for research applications focused on antibacterial resistance and infection treatment. -
Antibacterial
NR-NO2 is an innovative antibacterial agent that acts by producing reactive nitrogen species, thereby disrupting bacterial cell function. Its bioactivity involves the inhibition of bacterial growth, making it suitable for research applications in the development of new antibacterial therapies. Additionally, NR-NO2 offers potential in imaging-based guidance due to its unique targeting capabilities, enhancing its use in both antitumor and antibacterial research contexts. -
Metallo-β-lactamase Inhibitor
β-Lactamase-IN-7 is a potent inhibitor of VIM-type metallo-β-lactamases, exhibiting inhibition constants (Ki) of 1.26 μM and 0.54 μM for VIM-1 and VIM-4, respectively. This compound demonstrates effective inhibition against Klebsiella pneumoniae, making it valuable for studies focused on antibiotic resistance and the development of novel therapeutic strategies against resistant bacterial infections. Its role in characterizing metallo-β-lactamase activity positions it as an important tool in chemical biology research. -
Antibacterial/anticancer Agent
1-Hydroxy-3,5-dimethoxyxanthone, a xanthone derivative, serves as an effective antibacterial and anticancer agent. Isolated from Lomatogonium rotatum, this compound demonstrates inhibitory effects on the growth of Pseudomonas aeruginosa and Escherichia coli, achieving a minimum inhibitory concentration (MIC) of 640 μg/mL. Additionally, 1-Hydroxy-3,5-dimethoxyxanthone shows significant anticancer activity against various cancer types, including cervical, breast, melanoma, liver, and gastric cancers, making it a valuable tool for biological research and therapeutic development. -
Lipopeptide Antibiotic
Friulimicin D is a lipopeptide antibiotic derived from the actinomycete Actinoplanes friuliensis. It demonstrates significant antibacterial activity against a range of Gram-positive bacteria. Research applications include the study of bacterial resistance mechanisms and the potential development of novel antimicrobial therapies. -
Antibacterial Agent
4-Ethyloctane is a potent antibacterial agent targeting bacterial infections. Demonstrating strong activity against Staphylococcus aureus with a minimum inhibitory concentration (MIC) of 0.04 mg/mL, it serves as a valuable compound for the study of antibacterial properties and mechanisms. Researchers can utilize 4-Ethyloctane in investigations aimed at understanding bacterial resistance and the development of potential therapeutic applications. -
Antibacterial Agent
8-Hydroxy-9,10-diisobutyryloxythymol is a natural monoterpenoid that functions as an antibacterial agent. It demonstrates significant activity against various bacterial strains, including Staphylococcus aureus, Shigella flexneri, and Salmonella paratyphi-B, with minimal inhibitory concentration (MIC) values of 6.25 μg/mL. This compound is valuable for research in antimicrobial efficacy and the development of new antibacterial therapies. -
Antibacterial Agent
Antibacterial Agent 108 is a potent antibacterial compound targeting bacterial pathogens. It exhibits a minimum inhibitory concentration (MIC) of 3 μM against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. This compound is suitable for research applications in studying bacterial infections and developing new antibacterial therapies. -
Antibacterial Agent
Altromycin A is a natural antibacterial agent classified as a Pluramycin analog. It demonstrates significant activity against a range of bacterial strains, making it a valuable tool for studying bacterial infections and developing new antimicrobial strategies. Its mechanism of action involves interference with protein synthesis, which is critical for bacterial growth and survival. Research applications include antibiotic susceptibility testing and the investigation of resistance mechanisms. -
Antibacterial Agent
YXL-13 is a potent inhibitor of Pseudomonas aeruginosa (PAO1) with an IC50 value of 3.686 μM. This compound effectively targets the quorum sensing (QS) system, leading to inhibition of virulence factors and biofilm formation, thereby reducing both pathogenicity and antibiotic resistance. YXL-13 is suitable for research applications focused on the development of antibacterial strategies against PAO1 infections. -
Antibacterial Agent
11-Keto fusidic acid is an antibacterial agent that demonstrates potent activity against Staphylococcus aureus, exhibiting a minimal inhibitory concentration (MIC) of 0.078 μg/mL. Its effectiveness makes it a valuable compound for research focused on microbial infections and the development of novel antibacterial therapies. This compound can aid in the exploration of resistance mechanisms and therapeutic strategies in bacterial pathogenesis. -
antibacterial
Emeguisin A is a depsidone that exhibits notable antibacterial activity. It has been shown to inhibit cell viability in human colon carcinoma (HCT-116) cells by approximately 87.06%. This compound is valuable for research applications focused on developing antibacterial agents and studying the effects of natural products on cancer cell lines. -
Anti-Bacterial Agent
Saframycin F is an anti-bacterial agent primarily targeting Gram-positive bacteria. It demonstrates potent inhibitory activity against mouse lymphocyte L-1210, with an ID50 of 0.59 μM. This compound is useful in research applications focused on antibacterial activity and immune response modulation. -
Antibacterial Agent
Antibacterial Agent 321 is a lipophilic compound that targets bacterial cell membranes, inducing structural disruption. This agent exhibits phototoxic effects against both Staphylococcus aureus and Escherichia coli, demonstrating significant antibacterial activity. Antibacterial Agent 321 is suitable for research applications focusing on bacterial infection mechanisms and therapeutic interventions. -
Antibacterial Agent
Antibacterial Agent 198 is a potent antibacterial compound targeting gram-positive bacteria, specifically Staphylococcus aureus and various Enterococcus strains. This reagent exhibits significant antibacterial activity, making it a valuable tool for research focused on bacterial resistance and infection control mechanisms. Its application in microbiological studies provides insights into the efficacy of antibacterial agents and contributes to the development of new therapeutic strategies. -
CCR6 Antagonist
CCR6 antagonist 1 is a selective antagonist of the CCR6 receptor, effectively inhibiting the CCL20/CCR6 signaling pathway. This compound is instrumental in research focusing on autoimmune-mediated inflammatory diseases, particularly inflammatory bowel diseases (IBDs). Its role in modulating the CCR6 axis provides insights into potential therapeutic strategies for managing such conditions. -
CCR Antagonist
Abaucin is a potent CCR2 antagonist, demonstrating an IC50 of 360 nM. It selectively inhibits CCR2 without affecting CCR1, making it a valuable tool for studying immunological responses and inflammatory processes. Abaucin is applicable in research focusing on the role of CCR2 in disease models and therapeutic interventions targeting chemokine receptors. -
CCR Inhibitor
CCR6 Inhibitor 1 is a highly selective inhibitor of the CCR6 receptor, demonstrating IC50 values of 0.45 nM for monkey CCR6 and 6 nM for human CCR6, while exhibiting minimal activity against human CCR1 and CCR7. This inhibitor effectively prevents ERK phosphorylation, making it a valuable tool in the study of signaling pathways. CCR6 Inhibitor 1 is employed in research focused on autoimmune diseases and cancer, facilitating insights into therapeutic strategies targeting CCR6-related pathways. -
CCR7 Antagonist
CCR7 Ligand 1 is a potent allosteric antagonist targeting the human CC chemokine receptor 7 (CCR7), with a dissociation constant (Kd) of 3 nM. This thiadiazole-dioxide compound effectively inhibits arrestin binding upon CCL19 activation, exhibiting an IC50 of 7.3 μM. CCR7 Ligand 1 is valuable for research applications focused on immune response modulation, chemokine signaling pathways, and therapeutic development for related conditions. -
CCR4 Inhibitor
Zelnecirnon is an orally active CCR4 inhibitor that effectively blocks the recruitment of Th2 inflammatory immune cells to inflamed tissues. This compound exhibits potent anti-inflammatory activity, making it valuable in researching allergic inflammation associated with conditions such as atopic dermatitis and asthma. Zelnecirnon serves as a critical tool for understanding and developing therapeutic strategies in inflammatory diseases. -
CCR1 Antagonist
J-113863 is a potent and selective antagonist of the CCR1 receptor, demonstrating IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1, respectively. Additionally, it acts as a strong antagonist of the human CCR3 receptor (IC50 of 0.58 nM), while exhibiting weak antagonistic activity against mouse CCR3 (IC50 of 460 nM). J-113863 shows inactivity toward CCR2, CCR4, and CCR5, as well as LTB4 and TNF-α receptors. This compound is primarily utilized in anti-inflammatory research applications. -
CCR4 Antagonist
C-021 dihydrochloride is a highly effective antagonist of the CC chemokine receptor-4 (CCR4). It significantly inhibits chemotaxis in both human and mouse models, exhibiting IC50 values of 140 nM and 39 nM, respectively. Additionally, C-021 dihydrochloride demonstrates capability in preventing the binding of human CCL22-derived [35S]GTPγS to CCR4, with an IC50 of 18 nM. This compound is valuable for research applications focused on immune response modulation and related therapeutic strategies. -
CCR6 Antagonist
PF-07054894 is a potent and orally active antagonist of the C-C Chemokine Receptor 6 (CCR6), effectively blocking CCR6-mediated chemotaxis with an IC50 of 5.7 nM in vitro. As a target of G protein-coupled receptors (GPCRs), PF-07054894 demonstrates significant potential in the study of inflammatory bowel disease and related immunological disorders, providing a valuable tool for understanding CCR6’s role in inflammation. -
CCR4 Antagonist
C-021 is a potent antagonist of the CC chemokine receptor-4 (CCR4). It effectively inhibits functional chemotaxis in both human and mouse models, exhibiting IC50 values of 140 nM and 39 nM, respectively. Additionally, C-021 demonstrates strong efficacy in blocking the binding of human CCL22-derived [35S]GTPγS to CCR4, with an IC50 of 18 nM. This compound is valuable for research applications focused on immune response modulation and cancer biology. -
CCR10 Antagonist
BI-6901 is a potent and selective antagonist of the CCR10 receptor, exhibiting a pIC50 of 9.0. It demonstrates high selectivity among various GPCRs, including multiple chemokine receptors. BI-6901 has shown efficacy in the murine DNFB model of contact hypersensitivity, making it a valuable tool in inflammation research. -
CCR Antagonist
INCB 3284 is a selective and potent antagonist of the human CCR2 receptor, functioning by inhibiting the binding of monocyte chemoattractant protein-1 to hCCR2, with an IC50 value of 3.7 nM. This compound is of particular interest in studies related to acute liver failure, providing insights into the role of CCR2 signaling in inflammatory processes. Its oral bioavailability makes it a valuable tool for in vivo research applications. -
CCR4 Antagonist
Tivumecirnon is a selective CCR4 antagonist that functions by blocking the interaction of CCR4 with its ligands, CCL17 and CCL22. This mechanism reduces the infiltration of regulatory T cells (Tregs) into the tumor microenvironment, thereby enhancing antitumor activity. It is useful for research applications aimed at understanding immune modulation in cancer therapy. -
CCR2b Antagonist
CCR2 antagonist 4 hydrochloride is a selective antagonist targeting the CCR2b receptor, exhibiting a potent inhibitory effect with an IC50 value of 180 nM. This compound effectively reduces MCP-1-induced chemotaxis, with an IC50 of 24 nM, making it a valuable tool for studying inflammatory pathways. Its application in research includes investigations into immune responses and the role of CCR2 in various disease models, particularly those related to monocyte migration and chronic inflammation. -
CCR Inhibitor
Ilacirnon is a potent CCR2 antagonist that specifically targets the C-C chemokine receptor type 2 (CCR2). This compound exhibits significant inhibitory activity, making it valuable in research focused on inflammatory diseases and immune response modulation. Ilacirnon can be utilized in studies exploring the role of CCR2 in various pathophysiological conditions, including atherosclerosis and chronic kidney disease. -
CCR1 Antagonist
AZD-4818 is a potent, orally active antagonist of the chemokine receptor CCR1. This compound selectively inhibits CCR1 signaling, making it a valuable tool for studying the role of this receptor in various inflammatory conditions. Applications include research into chronic obstructive pulmonary disease (COPD) and other related respiratory disorders. -
CCR2 Antagonist
BMS CCR2 22 is a potent antagonist of CC-type chemokine receptor 2 (CCR2), exhibiting a high binding affinity with an IC50 value of 5.1 nM. This compound demonstrates strong functional antagonism, as evidenced by its calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM. BMS CCR2 22 is valuable for research applications targeting inflammatory responses and immune cell trafficking, providing insights into CCR2-related pathways. -
CCR Antagonist
MK-0812 Succinate is a potent and selective antagonist of the CCR2 receptor. It demonstrates high affinity for CCR2 and effectively inhibits its signaling pathway, making it a valuable tool for research into inflammatory and immune response processes. This compound is particularly relevant for studies focused on chronic pain, cardiovascular diseases, and various inflammatory disorders. -
CCR9 Antagonist
Vercirnon sodium is a potent and selective antagonist of CCR9, acting primarily by inhibiting CCR9-mediated Ca2+ mobilization and chemotaxis. This compound demonstrates significant biological activity, exhibiting IC50 values of 5.4 nM for Ca2+ mobilization and 3.4 nM for chemotaxis in Molt-4 cells. Vercirnon sodium shows high selectivity for CCR9, with IC50 values greater than 10 μM for other CCR and CX3CR subtypes. It effectively inhibits CCL25-directed chemotaxis in both CCR9 splice forms, CCR9A and CCR9B, with IC50 values of 2.8 nM and 2.6 nM, respectively, making it a valuable tool for research in inflammatory responses and related pathways. -
CCR4 Antagonist
CCR4 Antagonist 4 is a selective and potent inhibitor of the CC chemokine receptor-4 (CCR4), exhibiting an IC50 of 0.02 μM. This compound effectively blocks MDC-mediated chemotaxis and Ca2+ mobilization, with IC50 values of 0.007 μM and 0.003 μM, respectively. CCR4 Antagonist 4 is valuable for investigations into allergic inflammation mechanisms and related therapeutic applications. -
CCR8 Antagonist
CCR8 antagonist 1 is a potent antagonist of human CCR8, exhibiting an inhibition constant (Ki) of 1.6 nM. This compound demonstrates high safety and metabolic stability, making it suitable for in vitro and in vivo studies. CCR8 antagonist 1 is valuable for researching conditions such as asthma and multiple sclerosis, where CCR8-mediated pathways play a significant role in disease progression. -
CCR2 Negative Allosteric Modulator
AZD2423 functions as a negative allosteric modulator of the CCR2 chemokine receptor, exhibiting potent selectivity and oral bioavailability. With an IC50 value of 1.2 nM for CCR2-mediated Ca2+ flux, this compound is valuable for investigating the role of CCR2 in various physiological and pathological processes. AZD2423 is useful in research applications related to inflammation, cancer, and immune system modulation.
